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Human bone marrow-derived stromal stem cells (hBMSC) exhibit multiple functions, including differentiation into skeletal cells
(progenitor function), hematopoiesis support, and immune regulation (nonprogenitor function).We have previously demonstrated
the presence of morphological and functional heterogeneity of hBMSC cultures. In the present study, we characterized in detail
two hTERT-BMSC clonal cell populations termed here CL1 and CL2 that represent an opposing phenotype with respect to
morphology, markers expression: alkaline phosphatase (ALP) and CD146, and ex vivo differentiation potential. CL1 differentiated
readily to osteoblasts, adipocytes, and chondrocytes as shown by expression of lineage specific genes and proteins. Whole genome
transcriptome profiling of CL1 versus CL2 revealed enrichment in CL1 of bone-, mineralization-, and skeletal muscle-related
genes, for example, ALP, POSTN, IGFBP5 BMP4, and CXCL12. On the other hand, CL2 transcriptome was enriched in immune
modulatory genes, for example,CD14, CD99,NOTCH3, CXCL6, CFB, andCFI. Furthermore, gene expressionmicroarray analysis of
osteoblast differentiated CL1 versus CL2 showed significant upregulation in CL1 of bone development and osteoblast differentiation
genes which included several homeobox genes: TBX15, HOXA2 andHOXA10, and IGF1, FGFR3, BMP6, MCAM, ITGA10, IGFBP5,
and ALP. siRNA-based downregulation of the ALP gene in CL1 impaired osteoblastic and adipocytic differentiation. Our studies
demonstrate the existence of molecular and functional heterogeneity in cultured hBMSC. ALP can be employed to identify
osteoblastic and adipocytic progenitor cells in the heterogeneous hBMSC cultures.
1. Introduction
Human bonemarrow stromal (also known as skeletal ormes-
enchymal) stem cells (hBMSC) are increasingly employed
in clinical trials for enhancing tissue regeneration following
injury [1]. Typically, hBMSC are isolated by their ability
to adhere to the plastic surfaces of in vitro culture plates.
However, the cultured hBMSC exhibit morphological hetero-
geneity suggesting the presence of functional heterogeneity
[2, 3]. It has also been suggested that the use of heterogeneous
cell populations in clinical trials of hBMSC-based therapies
caused variability in the observed treatment effects [4]. Thus,
for the efficient use of hBMSC in therapy, better cellular and
molecular characterization of hBMSC is required [1, 4].
There exist no specific markers that define the hBMSC
phenotype. The plastic-adherent hBMSC are defined by the
presence of surface expression of some CD surface markers
with variable sensitivity and specificity [1]. Single cell clonal
analysis revealed that only 25% of the cells are true stem
cells based on their ability to differentiate into osteoblasts,
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adipocytes, and chondrocytes (trilineage differentiation) and
to form heterotopic bone and bone marrow organ when
implanted in vivo subcutaneously in immune deficient mice
[5]. The identity of the remaining cells is not clarified, but
they may represent lineage-committed cells [3]. Therefore, it
is plausible that functional heterogeneity exists in cultured
hBMSC, reflecting the in vivo functional and developmental
heterogeneity of hBMSC [6].
In addition to their ability to differentiate into skeletal
tissue cells (known as progenitor function), hBMSC possess
immunomodulatory characteristics (known as nonprogen-
itor functions) [7]. It is not clear whether these different
functions are mediated by a number of independent sub-
populations within the hBMSC [2]. Only a few studies have
tried to identify the subpopulation within cultured hBMSC
based on surface markers, for example, STRO1 and alkaline
phosphatase (ALP), but limited molecular phenotyping has
been conducted [8].
We have previously demonstrated the presence of mor-
phological and functional heterogeneity of clones isolated
from telomerized hMSC (hMSC-TERT) cell line [3].The aim
of the present study was therefore to further study in detail
the heterogeneity of cultured hBMSC as demonstrated by
two clonal cell lines with opposite cellular and functional
phenotype.We also employed theDNAmicroarrays to define
their molecular signature and signaling pathways associated
with their functional phenotype.
2. Experimental Procedures
2.1. Cell Culture. As a model for hBMSC, we employed
immortalized hBMSC-TERT cell line that is created from
normal human BMSC by overexpression of human telom-
erase reverse transcriptase gene (hTERT) [9]. The hBMSC-
TERT cells have been extensively characterized, and they
exhibit similar cellular and molecular phenotype to primary
MSC [10]. CL1 and CL2 cells are clonal cell populations
of hBMSC-TERT identified in long term culture (passage
numbers 15–25) of hBMSC-TERT and were chosen based on
their distinct and different morphologies. Cells were cultured
in Dulbecco’s Modified Eagle Medium (DMEM) supple-
mented with D-glucose 4500mg/L, 4mM L-glutamine and
110mg/L sodium pyruvate, 10% Fetal Bovine Serum (FBS), 1x
penicillin-streptomycin (Pen-strep), and nonessential amino
acids (all purchased from Gibco-Invitrogen, USA). For some
control experiments, primary bone marrow derived MSC
(phBMSC) were employed. Sixty milliliters of bone marrow
was aspirated from the iliac crest bone of consenting healthy
donors. This procedure was approved by the King Khalid
University Hospital-King Saud University ethics committee.
phBMSCwere isolated from bonemarrowmononuclear cells
by plastic adherence as described previously [9].
2.2. Cell Proliferation. Cell proliferation rate was determined
by counting cell number and calculating population doubling
(PD) rate. The cells were cultured in 25 cm2 tissue culture
Petri dish at cell density 0.5 × 106 cells (28000 cells/cm2). At
confluence, the cells were trypsinized and counted manually
by hemocytometer. At each passage, population doubling was
determined by the following formula: log𝑁/ log 2, where 𝑁
is the number of cells at confluence divided by the initial
cell number. Cumulative PD level is the sum of population
doublings, and PD rate is PD/time in culture.
2.3. Flow Cytometry. Cells were trypsinized to a single
cell suspension, were recovered by centrifugation at 200 g
for 5min, washed twice in ice-cold PBS supplemented
with 2% BSA, and resuspended at a concentration of
105 cells/antibody. After incubation with the preconjugated
antibodies, or matched isotype controls, for 30min on ice
in the dark, cells were washed with PBS, resuspended in
500𝜇L of PBS, and analyzed in the BD FACSCalibur flow
cytometer (BD Biosciences). Living cells were gated in a
dot plot of forward versus side scatter signals acquired on
a linear scale. At least 10,000 gated events were acquired
on a log fluorescence scale. Positive staining was distinct as
the emission of a fluorescence signal that surpassed levels
achieved by >99% of control cell population stained with
corresponding isotype antibodies. The ratios of fluorescence
signals versus scatter signals were calculated, and histograms
were generated using the software Cell Quest Pro Software
Version 3.3 (BD Biosciences). The following antibodies were
used all from BD Biosciences: FITC-PE-APC-Mouse IgG1k
isotype control, APC-Mouse Anti-Human CD44 (#559942),
FITC-Mouse Anti-HumanCD63 (#557305), PE-Mouse Anti-
Human CD73 (#550257), PE-Mouse Anti-Human CD105
(#560839), PE-Mouse Anti-Human CD146 (#550315), PE-
Mouse Anti-HumanCD166 (#560903), and Alexa Fluor 488
Mouse Anti-Human Alkaline Phosphatase (#561495).
2.4. Electron Microscopy. After trypsinizing the hBMSC cells
from the flasks or 6-well plates were collected, the samples
were washed with PBS, and the pellets were resuspended
directly in 2.5% glutaraldehyde in 0.1M phosphate buffer (pH
7.2), and kept at 4∘C for 4 hr. First, the cells were washed with
0.1Mphosphate buffer (pH7.2) and transferred to 1%osmium
tetroxide (OsO4) solution in 0.1M phosphate buffer (pH 7.2)
for two hr. The cells were dehydrated in ascending grades of
ethanol.The cells were then resuspended in acetone and were
aliquoted into BEEM embedding capsules and infiltrated
with acetone: resin mixture followed by embedding in a
pure resin mixture for two hr. Semithin sections (0.5 𝜇m
thickness) and ultrathin sections (70 nm thickness) were
prepared, examined, and photographed under a transmission
electron microscope (TEM) (Jeol 1010, Jeol, Tokyo, Japan).
2.5. In Vitro Osteoblast Differentiation. Cells were grown
in standard DMEM growth medium in 6-well plates at
20,000 cell/cm2. When 70–80% confluence was achieved, test
cells were cultured inDMEM supplementedwith osteoblastic
induction mixture (referred to as OS) containing 10% FBS,
1% Pen-strep, 50𝜇g/mL L-ascorbic acid (Wako Chemicals,
Neuss, Germany), 10mM 𝛽-glycerophosphate (Sigma) and
10 nM calcitriol (1𝛼,25-dihydroxyvitamin D3; Sigma), and
10 nM dexamethasone (Sigma); noninduced cells (referred
to as Cont) were cultured in normal growth media for the
same duration as induced. The media were replaced three
times per week. Cells cultured in standard culture medium
were considered as control. At day 14 of differentiation,
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mineralized nodules became apparent and were stained with
Alizarin Red S and ALP.
2.6. In Vitro Adipocyte Differentiation. Cells were grown in
standard DMEM growth medium in 6-well plates at 0.3
× 106 cells/mL. At 90–100% confluence, cells were cultured
in DMEM supplemented with adipogenic (Adip) induction
mixture containing 10% FBS, 10% Horse Serum (Sigma),
1% Pen-strep, 100 nM dexamethasone, 0.45mM isobutyl
methylxanthine (Sigma), 3𝜇g/mL insulin (Sigma), and 1 𝜇M
Rosiglitazone (Novo Nordisk, Bagsvaerd, Denmark). The
media were replaced three times per week. Cells cultured in
standard culture medium were considered as control. From
day 3 of differentiation, small lipid droplets became visible
and at day 7 they were stained with Oil Red-O and Nile red.
2.7. In Vitro Chondrogenic Differentiation. Both CL1 and CL2
cells were trypsinized and counted, around 1 × 106 cells
taken in each 15mL conical tube centrifuged at 400×g for
5 minutes. For chondrocyte differentiation pellet culture
system used, chondrocyte induction was done in media
containing advanced DMEM/F12 supplemented with 1% ITS
Premix Tissue Culture Supplement, 100 nM dexamethasone,
Glutamax, and 10 ng/mL transforming growth factor-beta-3
(TGF𝛽-3). Cells were maintained in chondrocyte differentia-
tion media for 21 days and changed every two days.
2.8. Cytochemical Staining
2.8.1. Alkaline Phosphatase (ALP) Staining. CL1 and CL2 cells
were stained before OS differentiation for the basal ALP
expression and after OB differentiation at day 7 of induction.
Cells cultured in 6-well plates were washed in PBS −/−
(-Ca, -Mg) andfixed in acetone/citrate buffer 10mMat pH4.2
for 5min at room temperature. The Naphthol/Fast Red stain
[0.2mg/mL Naphthol AS-TR phosphate substrate (Sigma)]
[0.417mg/mL of Fast Red (Sigma)] was added for one hour
at room temperature.
Histological tissue blocks were sectioned at 4 microns.
Immunohistochemical staining was performed on CL1 and
CL2 chondrocyte 3D pellets using DAKO EnVision and
PowerVision according to the manufacturer’s instructions
(DAKO, Glostrup, Denmark). Briefly, paraffin sections were
incubated for 1 hour at room temperature with primary
antibodies diluted in ChemMate (DAKO) (HumanAnti-Col-
10 and Human Anti-Col-2 ABI). Sections were washed sub-
sequently in Tris-buffered saline (TBS, 0.05M, pH 7.4), incu-
bated for 30 minutes with secondary anti-mouse Ig/HRP-
conjugated polymers (K4001, En Visionþ, DAKO), and visu-
alizedwith 3,30-diaminobenzidine tetrahydrochloride (DAB,
S3000, DAKO) or with 3-amino-9-ethylcarbazole (AEC,
DAKO) according to manufacturer’s instruction. Controls
were performed with nonimmune immunoglobulins of the
same isotype as the primary antibodies (negative controls)
and processed under identical conditions. Alcian blue stain-
ing was used to detect chondrocytes. Sections of paraffin-
embedded implants were stained with Alcian blue (Sigma)
solution, pH 2.5; at this pH all the glycoproteins (neutral and
acidic) will be stained blue.
2.9. Alizarin Red S Staining for Mineralized Matrix. Seven-
day-old OS differentiated cells in 6-well plates were used for
Alizarin Red S staining. The cell layer was washed with PBS
and then fixed with 70% ice-cold ethanol for 1 hr at −20∘C.
After removing the ethanol, the cell layer was rinsed with
distilled water and stained with 40 nM AR-S (Sigma) pH 4.2
for 10 minutes at room temperature. Excess dye was washed
off with water followed by a wash with PBS for few minutes
to minimize nonspecific AR-S stain.
For quantifying the Alizarin Red S staining, the air-dried
plates, the Alizarin Red S dye was eluted in 800 𝜇L of acetic
acid incubated in each well for 30 minutes at room temper-
ature as described [11] and measured in spectrophotometer
(BioTek, Epoch) at 405 nm.
2.10. Quantitative ALP Activity. To quantify ALP activity in
CL1 and CL2 hBMSC before and after OS differentiation,
we used the BioVision ALP activity colorimetric assay kit
(BioVision, Inc, CA, USA) with some modifications. Cells
were cultured in 96-well plates under normal conditions;
then on day of analysis, wells were rinsed once with PBS
and were fixed using 3.7% formaldehyde in 90% ethanol for
30 seconds at room temperature. Subsequently, fixative was
removed, and 50𝜇L of pNPP solution was added to each well
and incubated for 1 hour in the dark at room temperature.
The reaction was subsequently stopped by adding 20 𝜇L stop
solution and gently shaking the plate. ODwas thenmeasured
at 405 nm.
2.11. Oil Red-O Staining for Lipid Droplets. CL1 and CL2 cells
differentiated to adipocytes with Adip induction media at
day 7 were used. Accumulated cytoplasmic lipid droplets
were visualized by staining with Oil Red-O. After washing
cells grown in 6-well plates with PBS, the cells were fixed
in 4% formaldehyde for 10min at room temperature and
then rinsed once with 3% isopropanol and stained for 1 hr at
room temperature with filtered Oil Red-O staining solution
(prepared by dissolving 0.5 g Oil Red-O powder in 60%
isopropanol). To quantify staining of fat droplets, Oil Red-
O was used as a stain. Oil Red-O was eluted by adding 100%
isopropanol to each well, and color changes were measured
by spectrophotometer at 510 nm (BioTek Spectrophotometer,
Epoch).
2.12. Nile Red Fluorescence Determination and Quantification
of Adipogenesis. A stock solution of Nile red (1mg/mL) in
DMSO was prepared and stored at −20∘C protected from
light. Staining was performed on unfixed cells. Cultured
undifferentiated and day 7 adipocyte differentiated cells were
grown in Corning polystyrene; flat bottom 96-well TC-
treated black microplates (Corning, NY, USA) were washed
once with PBS. The dye was then added directly to the cells
(5 𝜇g/mL in PBS), and the preparation was incubated for
10min at room temperature and then washed twice with PBS.
Fluorescent signal was measured using SpectraMax/M5 fluo-
rescence spectrophotometer plate reader (Molecular Devices
Co, Sunnyvale, CA, USA) using bottom well-scan mode
where nine readings were taken per well using Ex (485 nm)
and Em (572 nm) spectra.
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2.13. Quantitative Real-Time PCR (qRT-PCR) Analysis. Total
RNA was extracted using MagNA pure compact RNA iso-
lation kit (Roche Applied Science, Germany, Cat number
04802993001) in an automatedMagNA pure compact system
(Roche, Germany) as recommended by the manufacturer.
The total RNAwas quantified by Nanodrop spectrophotome-
ter (Nanodrop 2000, Thermo Scientific, USA). Complemen-
tary DNA (cDNA) was synthesized from 1 𝜇g of the RNA
samples usingHighCapacity cDNAReverse Transcription kit
(Applied Biosystems, USA) using Labnet, Multigene thermo-
cycler according to the manufacturer’s instructions. Relative
levels of mRNA were determined from cDNA by real-time
PCR (Applied Biosystems-Real-Time PCRDetection System)
with Power SYBR Green PCR kit (Applied Biosystems,
UK) according to the manufacturer’s instructions. Following
normalization to the reference gene GAPDH, quantification
of gene expression was carried out using a comparative Ct
method, where ΔCt is the difference between the CT values
of the target and the reference gene, and fold induction was
performed from the control (Cont) for the same time point.
Primers (Supplementary Table 1 in Supplementary Material
available online at http://dx.doi.org/10.1155/2016/9378081)
were obtained from Applied Biosystems (USA) as TAQMAN
primers, or previously published primers were used (see
Supplementary Table 1).
2.14. DNAMicroarray Global Gene Expression Analysis. Four
hundred ng of total RNA was used as input for gener-
ating biotin-labeled cRNA (Ambion, Austin, TX, United
States). cRNA samples were then hybridized onto Illumina
human-8 BeadChips version 3. Hybridization, washing, Cy3-
streptavidin staining, and scanning were performed on the
Illumina BeadStation 500 platform (Illumina, San Diego,
CA, USA), according to the manufacturer’s instructions, and
everything was done in triplicate. Expression data analysis
was carried out using the Partek genomic suite software.
Raw data were background-subtracted, normalized using
the “rank invariant” algorithm, and filtered for significant
expression on the basis of negative control beads. Genes
were considered significantly expressed with detection 𝑝
values ≤ 0.01. Differential expression analysis was performed
with the Illumina custom method using freshly isolated
primary hBMSC (used at passage 3) as a reference control.
The following parameters were set to identify statistical
significance: differential 𝑝 values ≤ 0.01; fold change ratio
> 1.5. Pathway analysis was performed using DAVID Bioin-
formatics Resources 6.7 (http://david.abcc.ncifcrf.gov/) and
GeneSpring GX software (Agilent Technologies). Pathway
analysis for CL1 OS D14 versus CL2 OS D14 was conducted
using the Single Experiment Pathway analysis feature in
GeneSpring 12.0 (Agilent Technologies).
2.15. Small Interfering (si)RNATransfection. For transfection,
hBMSC in logarithmic growth phase were transfected with
Silencer Select Predesigned ALP siRNA (25 nM) (Assay ID;
s1298 and Cat number 4390824) (Ambion, The RNA Com-
pany, USA) using Lipofectamine RNAiMAX Reagent (Invit-
rogen, CA, USA) plus serum-free Opti-MEMI medium
under the conditions described by the manufacturer. At
day 3 of transfection, the cells were induced for osteogenic
differentiation for an additional 7 days. ALP staining was
used as a control for the siRNA transfection efficiency and
timeline.
2.16. Statistical Analysis. All of the results were presented
as the mean and standard deviation (SD) of at least 3
independent experiments, with 3–5 technical repeats in each
experiment. Student’s 𝑡-test (two-tailed) was used for testing
differences between groups. 𝑝 value <0.05 was considered
statistically significant.
3. Results
3.1. Comparison between CL1 and CL2: Differences in Mor-
phology, Proliferation, and Marker Expression Profile. We
isolated two distinct clonal cell populations of hBMSC-TERT:
hBMSC-CL1 and hBMSC-CL2 (for easiness will be termed
hereafter CL1 and CL2) based on differences in cell morphol-
ogy (Figure 1(a)). CL1 cells had cuboidalmorphologywhereas
CL2 cells have spindle-shaped fibroblast-like morphology.
CL1 cells had higher proliferation rate compared to CL2
(Figure 1(b)): mean PD rates of CL1 and CL2 were 0.714 and
0.429 PD/day, respectively (Figure 1(b)). Both CL1 and CL2
expressed surface marker profiles characteristics of hBMSC
(>90%): CD44+, CD63+, CD73+, CD105+, and CD166+
(Figure 1(c)). However CL1 cells showed higher expression
of CD146 (92.7% versus 12%) and ALP (98% versus 0%)
compared to CL2 (Figure 1(d)). TEM revealed the presence
of abundant pseudopodia in CL1 indicating high motility
(Figure 1(e)(A)) as well as well-developed mitochondria
and rough endoplasmic reticulum (rER) suggesting high
metabolic activity. CL2 cells contained abundant phagocytic
vacuole (pv),microvilli (mi), and lysosomes (ly) (Figure 1(e)).
We performed quantitative real-time PCR (RT-PCR)
for genes expressed in mesodermal progenitor cells [12].
CL1 expressed higher levels of BMP4, MIXL1, WNT3a, and
TWIST compared to CL2 (Figure 1(f), 𝑝 < 0.01). In contrast,
CL2 expressed higher levels of Kinase Insert Domain Recep-
tor (Type III Receptor Tyrosine Kinase) (KDR) expressed in
endothelial cells and smoothmusclemyosin heavy chain gene
(smMHC) expressed in smooth muscle cells (Figure 1(f)).
3.2. CL1 Cells Exhibit Enhanced Osteoblast Differentiation.
Following osteoblast (OB) differentiation induction, ALP
staining andALP enzymatic activity were significantly higher
in CL1 compared to CL2 cells (Figure 2(a), 𝑝 < 0.01).
Similarly, Alizarin Red staining and quantitation of formed
mineralized matrix were more pronounced in CL1 cells (Fig-
ure 2(b), 𝑝 < 0.01). In addition, CL1 cells expressed higher
levels of osteoblastic genes, ALP, RUNX2, and osteopontin
(OPN) (Figure 2(c) upper panel) compared to CL2 cells.
Global gene expression microarray analysis of OB dif-
ferentiated cells at day 14 showed around 1060 genes signif-
icantly upregulated more than 2-fold (𝑝 < 0.01) in CL1.
Among the upregulated genes, 80 genes were annotated to
bone development and osteoblast differentiation (Table 1).
The highest upregulated genes included paired-like home-
odomain 2 (PITX2), Insulin-like growth factor 1 (IGF1) and
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Figure 1: Cellular phenotype of two clonal populations of humanbonemarrow stromal stem cells: CL1 andCL2. (a) Cellmorphology. CL1 cells
showed large cuboidal morphology while CL2 cells had spindle-shaped fibroblast-like morphology. (b) Growth curves showing population
doubling (PD) rate during long term culture. (c) Flow cytometry analysis (FACS) shows expression of CD44, CD63, CD73, CD105, andCD166
in CL1 and CL2 cells. Matched isotype control was used for gating. (d) Flow cytometry analysis presented as dot blot of CD146 and alkaline
phosphatase (ALP) cell surface proteins. (e) Transmission electron microscope (TEM). (A): CL1 (1200x); (B): CL2 (1500x). n: nucleus, nu:
nucleolus, rER: rough endoplasmic reticulum, ly: lysosomes, pv: phagocytic vacuole, and rer: reticular stalk of rER. (f) Gene expression
analysis using RT-PCR for a group of mesodermal and stromal genes. Gene expression was normalized to GAPDH and presented as fold
change. Data is shown as mean ± SD of three independent experiments. ∗𝑝 < 0.05; #𝑝 < 0.001.
collagen, type V, alpha 3 (COL5A3), osteomodulin (OMD),
and T-box 15 (TBX15) (Table 1). Furthermore, several known
osteoblast-related genes were upregulated in CL1 cells such
as bone morphogenetic protein 6 (BMP6), fibroblast growth
factor receptor 3 (FGFR3), insulin-like growth factor binding
protein 5 (IGFBP5), and vitamin D (1,25-dihydroxyvitamin
D3) receptor (VDR) (Table 1). On the other hand, 1200 genes
were upregulated in CL2 cells: 255 genes were annotated to
immunity and immune response and defense. This category
included genes from, complement system, chemokine (C-C
motif) ligands, interferon family, chemokine (C-X-C motif)
ligands, and receptor, major histocompatibility complex class
II molecules, interleukins, and tumor necrosis factor receptor
superfamily (Table 2 and Supplementary Table 3).
3.3. CL1 Cells Exhibit Enhanced Adipocyte Differentiation.
We observed significant differences between CL1 and CL2
in their response to adipocytic differentiation induction.
CL1 differentiated readily to adipocytes compared to CL2
(Figure 2(d), lower panel) evidenced by higher levels of
adipocyticmarkers gene expression, LPL (lipoprotein lipase),
and adiponectin, as well as formation of mature lipid filled
adipocytes visualized by Oil Red-O staining and quantitative
Nile red staining (Figure 2(d)).
3.4. CL1 Cells Differentiate to Chondrocytic Lineage. In
pellet cultures, CL1 cells formed 3D pellets containing
proteoglycan-secreting chondrocytes, which stained positive
with Alcian blue. Limited chondrocyte differentiation was
visible in cell pellets of CL2 cells. The differentiated chon-
drocytes in CL1 pellets expressed higher levels of collagen X
and collagen II, which was overlapping the Alcian blue stain
(Figure 2(e)).
3.5. Molecular Signature of CL1 and CL2 Cells. To define the
molecular signature and molecular differences between CL1
and CL2, we compared the basal gene expression pattern
of CL1 and CL2 cells using DNA microarrays. The PCA
analysis showed a clear separation between CL1 and CL2
(Supplementary Figure 1). Comparison between CL1 with
CL2 showed that 915 geneswere differentially expressed in the
two cell lines (>2-fold,𝑝 < 0.01): 462 genes were upregulated,
and 452 were downregulated in CL1 versus CL2. The most
relevant genes that were upregulated in CL1 are listed in
Table 3(a). Among these 35 highly expressed genes in CL1, the
following 11 genes were present in skeletal and muscular sys-
tem development and function: FOLR3, CCL3L1, SERPINB2,
POSTN, IGFBP5, CCL3, NOV, ALP, TNFRSF11B, ACTG2,
and CDH11 (Table 3(a)). Functional annotation of the upreg-
ulated genes in CL1 using the Ingenuity Pathway Analysis
(IPA) revealed enrichment in the following categories: “tissue
development,” “skeletal and muscular system development
and function,” and “organismal development” (Table 3(b)).
Furthermore, the DAVID annotation tool was employed to
assess the functional relationships of the upregulated genes
in CL1 showing enrichment in ontologies: “skeletal and
muscular system development and function” that included
bone size, osteoblast differentiation, bone mineralization,
and bone mineral density (Table 3(c)). CL1 exhibited upreg-
ulation of WNT pathway ligands: WNT5B (2-fold) and
LRP5 (2-fold) (Table 1). Also, ALP was among the highly
expressed genes together with POSTN, IGFBP5, SPP1, IL-
6, and DKK1 (Tables 3(a) and 1). These genes are known
to play an important role in osteoblast differentiation and
bone formation. For CL2, inhibitors of WNT pathway were
upregulated and included SFRP1 (11-fold), DKK2 (3.2-fold),
FGF2 (3.1-fold), and GBP2 (2.4-fold). Functional annotation
of the upregulated genes in CL2 revealed enrichment in the
following categories: “developmental process,” “multicellular
organismal process,” “biological adhesion,” and “immune
system process” (Supplementary Table 2A). In-depth analysis
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Figure 2: In vitro osteoblastic and adipocytic differentiation of two clonal populations of human bone marrow stromal stem cells: CL1 and
CL2 cells. Both cell lines were induced for osteoblast differentiation using standard protocol described in the Methods. (a) ALP staining at
day 14 in control noninduced (Cont) and osteoblast induced cells (D14). Right panel shows ALP activity (𝑛 = 3 independent experiments,
#
𝑝 < 0.001). (b) Mineralized matrix formation visualized by Alizarin Red S staining. Right panel shows Alizarin Red quantification at day 14
and 21 after osteoblast differentiation (𝑛 = 3 independent experiments, #𝑝 < 0.001). (c) Quantitative RT-PCR of osteoblastic and adipocyte
gene markers in CL1 and CL2 during osteoblast (upper panel) and adipocyte (lower panel) differentiation. ALP = alkaline phosphatase,
OPN = osteopontin, LPL = lipoprotein lipase, and ADIPOQ = adiponectin. Data are presented as fold change in expression of each target
gene normalized to GAPDH (𝑛 = 3 independent experiments, 𝑝 < 0.05; #𝑝 < 0.001). (d) CL1 and CL2 lines were induced for adipocyte
differentiation using standard protocol described in the Methods. Adipocyte formation was visualized at day 7 (Adip d7) and day 14 (Adip
d14) by Oil Red-O staining. Lower panel presents quantification of Nile red staining (𝑛 = 3 independent experiments, #𝑝 < 0.001). (e) CL1
and CL2 lines were induced for chondrocyte differentiation using 21-day pellet culture method as described in the Methods. The pellets were
stained with Alcian blue, collagen 10 (Col X), and collagen 2 (Col II) (original magnification 5x).
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Table 1: Microarray data analysis showing genes related to bone development and osteoblast differentiation upregulated in CL1 versus CL2
cells.
Probe ID Genbank accession Gene name Gene symbol FC
A 23 P167367 NM 153426 Paired-like homeodomain 2 PITX2 308.84
A 23 P13907 NM 000618 Insulin-like growth factor 1 (somatomedinC) IGF1 118.00
A 23 P55749 NM 015719 Collagen, type V, alpha 3 COL5A3 75.11
A 23 P94397 NM 005014 Osteomodulin OMD 56.07
A 24 P128442 NM 152380 T-box 15 TBX15 54.38
A 33 P3708413 NM 003480 Microfibrillar associated protein 5 MFAP5 53.73
A 24 P72064 NM 000163 Growth hormone receptor GHR 51.47
A 23 P215454 NM 001278939 Elastin ELN 50.15
A 24 P200854 NM 006735 Homeobox A2 HOXA2 44.99
A 23 P19624 NM 001718 Bone morphogenetic protein 6 BMP6 41.43
A 23 P500501 NM 000142 Fibroblast growth factor receptor 3 FGFR3 33.95
A 23 P154605 NM 018837 Sulfatase 2 SULF2 29.57
A 23 P28815 NM 000782 Cytochrome P450, family 24, subfamily A,polypeptide 1 CYP24A1 22.47
A 23 P210109 NM 019885 Cytochrome P450, family 26, subfamily B,polypeptide 1 CYP26B1 22.42
A 23 P323180 NM 006898 Homeobox D3 HOXD3 21.08
A 32 P405759 NM 152888 Collagen, type XXII, alpha 1 COL22A1 20.36
A 33 P3363799 NM 001242607 Neural cell adhesion molecule 1 NCAM1 17.33
A 33 P3381378 NM 001257096 Paired box 1 PAX1 17.12
A 23 P383009 NM 000599 Insulin-like growth factor binding protein 5 IGFBP5 14.67
A 33 P3382856 NM 133507 Decorin DCN 14.38
A 23 P10206 NM 005328 Hyaluronan synthase 2 HAS2 14.33
A 24 P77904 NM 018951 Homeobox A10 HOXA10 13.64
A 23 P2814 NM 005905 SMAD family member 9 SMAD9 12.45
A 23 P88404 NM 003239 Transforming growth factor, beta 3 TGFB3 12.11
A 32 P4595 NM 000337 Sarcoglycan, delta (35 kDadystrophin-associated glycoprotein) SGCD 8.95
A 23 P162171 NM 006500 Melanoma cell adhesion molecule MCAM 8.60
A 24 P38276 NM 003505 Frizzled class receptor 1 FZD1 7.81
A 23 P24129 NM 012242 Dickkopf WNT signaling pathway inhibitor1 DKK1 7.04
A 33 P3264528 NM 005523 Homeobox A11 HOXA11 6.64
A 33 P3220470 NM 005585 SMAD family member 6 SMAD6 6.47
A 23 P23783 NM 000261 Myocilin, trabecular meshwork inducibleglucocorticoid response MYOC 6.41
A 33 P3263432 NM 003637 Integrin, alpha 10 ITGA10 6.35
A 23 P383009 NM 000599 Insulin-like growth factor binding protein 5 IGFBP5 6.18
A 33 P3219090 NM 005542 Insulin induced gene 1 INSIG1 5.78
A 23 P162589 NM 001017535 Vitamin D (1,25-dihydroxyvitamin D3)receptor VDR 5.68
A 23 P374695 NM 000459 TEK tyrosine kinase, endothelial TEK 5.65
A 24 P261169 NM 006378
Sema domain, immunoglobulin domain
(Ig), transmembrane domain (TM), and
short cytoplasmic domain, (semaphorin) 4D
SEMA4D 5.41
A 33 P3297930 NM 005202 Collagen, type VIII, alpha 2 COL8A2 5.138
A 23 P206359 NM 004360 Cadherin 1, type 1, E-cadherin (epithelial) CDH1 5.12
A 24 P264943 NM 000095 Cartilage oligomeric matrix protein COMP 5.07
A 33 P3214948 NM 014767 Sparc/osteonectin, cwcv, and kazal-likedomains proteoglycan (testican) 2 SPOCK2 4.54
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Table 1: Continued.
Probe ID Genbank accession Gene name Gene symbol FC
A 24 P55496 NM 053001 Odd-skipped related transcription factor 2 OSR2 4.38
A 24 P354689 NM 004598 Sparc/osteonectin, cwcv, and kazal-likedomains proteoglycan (testican) 1 SPOCK1 4.23
A 23 P69030 NM 001850 Collagen, type VIII, alpha 1 COL8A1 3.93
A 23 P128084 NM 002206 Integrin, alpha 7 ITGA7 3.91
A 24 P3249 NM 000965 Retinoic acid receptor, beta RARB 3.91
A 24 P168574 AJ224867 GNAS complex locus GNAS 3.83
A 23 P320739 NM 002397 Myocyte enhancer factor 2C MEF2C 3.74
A 23 P429383 NM 014213 Homeobox D9 HOXD9 3.54
A 23 P42322 NM 080680 Collagen, type XI, alpha 2 COL11A2 3.42
A 23 P160318 NM 001856 Collagen, type XVI, alpha 1 COL16A1 3.36
A 33 P3407013 NM 000600 Interleukin 6 IL6 3.30
A 23 P315364 NM 002089 Chemokine (C-X-C motif) ligand 2 CXCL2 3.29
A 33 P3413168 BC007696 Collagen, type XXVII, alpha 1 COL27A1 3.08
A 23 P43164 NM 015170 Sulfatase 1 SULF1 3.05
A 23 P58676 NM 001204375 Natriuretic peptide receptor 3 NPR3 3.04
A 33 P3290562 NM 000168 GLI family zinc finger 3 GLI3 3.00
A 23 P69497 NM 003278 C-type lectin domain family 3, member B CLEC3B 2.99
A 24 P353619 NM 000478 Alkaline phosphatase, liver/bone/kidney ALPL 2.99
A 33 P3305749 NM 000965 Retinoic acid receptor, beta RARB 2.89
A 23 P307328 NM 007331 Wolf-Hirschhorn syndrome candidate 1 WHSC1 2.77
A 23 P152305 NM 001797 Cadherin 11, type 2, OB-cadherin(osteoblast) CDH11 2.77
A 23 P216361 NM 021110 Collagen, type XIV, alpha 1 COL14A1 2.62
A 23 P7313 NM 001040058 Secreted phosphoprotein 1 SPP1 2.60
A 24 P267592 NM 015474 SAM domain and HD domain 1 SAMHD1 2.54
A 23 P210482 NM 000022 Adenosine deaminase ADA 2.52
A 23 P148047 NM 000958 Prostaglandin E receptor 4 (subtype EP4) PTGER4 2.51
A 23 P345725 NM 014621 Homeobox D4 HOXD4 2.47
A 24 P125283 NM 001015053 Histone deacetylase 5 HDAC5 2.37
A 33 P3231953 NM 004370 Collagen, type XII, alpha 1 COL12A1 2.34
A 24 P298027 NM 004655 Axin 2 AXIN2 2.31
A 24 P336551 NM 199173 Bone gamma-carboxyglutamate (gla)protein BGLAP 2.29
A 33 P3313825 XM 006713316 Transforming growth factor, beta receptor II(70/80 kDa) TGFBR2 2.23
A 23 P82990 NM 033014 Osteoglycin OGN 2.20
A 32 P24585 NM 001017995 SH3 and PX domains 2B SH3PXD2B 2.20
A 24 P944458 NM 016133 Insulin induced gene 2 INSIG2 2.14
A 23 P99063 NM 002345 Lumican LUM 2.12
A 32 P5251 NM 001024809 Retinoic acid receptor, alpha RARA 2.11
A 24 P935491 NM 000090 Collagen, type III, alpha 1 COL3A1 2.10
A 33 P3312104 NM 025099 CTS telomere maintenance complexcomponent 1 CTC1 2.06
A 33 P3321342 NM 016133 Insulin induced gene 2 INSIG2 2.04
A 23 P100486 NM 206824 Vitamin K epoxide reductase complex,subunit 1 VKORC1 2.02
A 23 P53588 NM 030775 Wingless-type MMTV integration sitefamily, member 5B WNT5B 2.00
A 23 P616356 NM 001291902 Low density lipoprotein receptor-relatedprotein 5 LRP5 2.00
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Table 2: Microarray data analysis showing genes related immune modulation and immune defense genes upregulated in CL2 versus CL1
cells.
ID Gene name Gene symbol Fold change
A 23 P128094 ATP-binding cassette, subfamily B (MDR/TAP), member 9 ABCB9 2.1
A 32 P156963 Actin, gamma 1 ACTG1 3.0
A 23 P28279 ARP1 actin related protein 1 homolog B, centractin beta (yeast) ACTR1B 2.0
A 23 P211207 Adenosine deaminase, RNA-specific, B1 ADARB1 3.5
A 23 P381261 Adenylate cyclase 4 ADCY4 5.0
A 23 P169993 Adenylate cyclase 8 (brain) ADCY8 3.2
A 23 P76823 Adenylosuccinate synthase-like 1 ADSSL1 7.0
A 23 P135486 Alpha hemoglobin stabilizing protein AHSP 2.6
A 23 P216023 Angiopoietin 1 ANGPT1 7.6
A 23 P94501 Annexin A1 ANXA1 2.6
A 23 P121716 Annexin A3 ANXA3 346.8
A 23 P6398 Adaptor-related protein complex 1, beta 1 subunit AP1B1 2.2
A 23 P120931 Apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like3C APOBEC3C 2.2
A 23 P132316 Apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like3D APOBEC3D 2.4
A 23 P357101 Apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like3F APOBEC3F 2.3
A 23 P143713 Apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like3G APOBEC3G 9.6
A 23 P93988 Rho guanine nucleotide exchange factor (GEF) 5 ARHGEF5 8.7
A 24 P20383 Actin related protein 2/3 complex, subunit 4, 20 kDa ARPC4 2.2
A 23 P208389 AXL receptor tyrosine kinase AXL 2.0
A 33 P3279353 Azurocidin 1 AZU1 4.8
A 33 P3262043 BCL2-associated agonist of cell death BAD 2.3
A 24 P159648 BAI1-associated protein 2 BAIAP2 2.2
A 23 P370682 Basic leucine zipper transcription factor, ATF-like 2 BATF2 22.2
A 23 P160720 Basic leucine zipper transcription factor, ATF-like 3 BATF3 3.0
A 33 P3229272 Breast cancer antiestrogen resistance 1 BCAR1 3.3
A 23 P210886 BCL2-like 1 BCL2L1 3.4
A 23 P98350 Baculoviral IAP repeat containing 3 BIRC3 25.0
A 23 P31725 B lymphoid tyrosine kinase BLK 7.3
A 33 P3419785 BCL2/adenovirus E1B 19 kDa interacting protein 3 BNIP3 7.3
A 19 P00802936 BRICK1, SCAR/WAVE actin-nucleating complex subunit BRK1 2.2
A 23 P2431 Complement component 3a receptor 1 C3AR1 2.6
A 23 P97541 Complement component 4 binding protein, alpha C4BPA 2.6
A 23 P92928 Complement component 6 C6 4.0
A 23 P213857 Complement component 7 C7 2.2
A 33 P3745146 Cell adhesion molecule 1 CADM1 34.3
A 23 P250347 Calcium/calmodulin-dependent protein kinase IV CAMK4 3.4
A 23 P253791 Cathelicidin antimicrobial peptide CAMP 3.3
A 23 P82324 Caspase recruitment domain family, member 11 CARD11 7.9
A 23 P500433 Caspase recruitment domain family, member 9 CARD9 2.4
A 23 P202978 Caspase 1, apoptosis-related cysteine peptidase CASP1 2.4
A 23 P123853 Chemokine (C-C motif) ligand 19 CCL19 2.0
A 23 P17065 Chemokine (C-C motif) ligand 20 CCL20 14.6
A 23 P215484 Chemokine (C-C motif) ligand 26 CCL26 2.8
A 23 P503072 Chemokine (C-C motif) ligand 28 CCL28 4.3
A 33 P3316273 Chemokine (C-C motif) ligand 3 CCL3 2.3
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Table 2: Continued.
ID Gene name Gene symbol Fold change
A 23 P152838 Chemokine (C-C motif) ligand 5 CCL5 2.7
A 23 P78037 Chemokine (C-C motif) ligand 7 CCL7 16.0
A 23 P207456 Chemokine (C-C motif) ligand 8 CCL8 2.8
A 23 P361773 Cyclin D3 CCND3 2.3
A 33 P3284508 CD14 molecule CD14 4.2
A 23 P259863 CD177 molecule CD177 2.7
A 33 P3381513 CD274 molecule CD274 10.8
A 23 P15369 CD300 molecule-like family member b CD300LB 2.0
A 23 P416747 CD3e molecule, epsilon (CD3-TCR complex) CD3E 2.7
A 24 P188377 CD55 molecule, decay accelerating factor for complement (Cromerblood group) CD55 5.9
A 23 P300056 Cell division cycle 42 CDC42 4.5
A 32 P148710 Cofilin 1 (nonmuscle) CFL1 2.8
A 33 P3217584 Cholinergic receptor, nicotinic, alpha 4 (neuronal) CHRNA4 2.9
A 33 P3415300 Complexin 2 CPLX2 2.7
A 23 P133408 Colony stimulating factor 2 (granulocyte-macrophage) CSF2 16.5
A 33 P3396139 Cytotoxic T-lymphocyte-associated protein 4 CTLA4 3.0
A 33 P3287631 Cathepsin B CTSB 2.3
A 33 P3283480 Cathepsin C CTSC 8.2
A 23 P7144 Chemokine (C-X-C motif) ligand 1 (melanoma growth stimulatingactivity, alpha) CXCL1 6.5
A 33 P3712341 Chemokine (C-X-C motif) ligand 12 CXCL12 4.8
A 33 P3351249 Chemokine (C-X-C motif) ligand 16 CXCL16 11.6
A 23 P315364 Chemokine (C-X-C motif) ligand 2 CXCL2 3.3
A 24 P183150 Chemokine (C-X-C motif) ligand 3 CXCL3 2.9
A 23 P155755 Chemokine (C-X-C motif) ligand 6 CXCL6 5.0
A 33 P3214550 Chemokine (C-X-C motif) receptor 2 CXCR2 2.0
A 33 P3389230 Chemokine (C-X-C motif) receptor 3 CXCR3 2.3
of the biological processes revealed several immune-related
pathways: “MAPKKK cascade,” “immunity and defense,”
“signal transduction,” “extracellular matrix protein-mediated
signaling,” and “interferon-mediated immunity,” among oth-
ers that were upregulated (Supplementary Table 2B). Also,
40 genes related to immune system related factors were
identified as significantly enriched in CL2 compared to CL1
cells (Supplementary Table 2C).We chose the following genes
for validation of the microarray results: NOV, IGFBP5, ALP,
TAGLN, and CDH11 as they were highly expressed in CL1.
RT-PCR analysis confirmed themicroarray results (Figure 3).
Furthermore, we compared the molecular phenotype of
CL1 and CL2 cells with that of phBMSC.We found that more
than 80% of the genes expressed in CL1 and 90% in CL2 cells
were commonwith primary phBMSC (Supplementary Figure
2), suggesting that CL1 and CL2 molecular phenotype exist
within the heterogeneous population of phBMSC cultures.
3.6. ALP Knockdown Impairs Differentiation of CL1 Cells.
Since ALP has been suggested as a marker for hBMSC
progenitor cell lineage commitment [13] and was highly
upregulated in CL1 cells, we tested its biological role in
CL1 cells. ALP siRNA transfection decreased ALP protein
level, ALP activity, and mRNA gene expression compared to
control cells transfected with control siRNA (𝑝 < 0.01) and
this inhibition was detectable up to day 7 days after osteoblast
differentiation induction (Figures 4(A) and 4(B)). At day 14 of
differentiation, mineralization ability of CL1 was significantly
impaired (Figure 4(C)). In addition, we found that the
number of mature adipocyte formations was significantly
reduced to more than 75% (𝑝 < 0.01) (Figure 4(D)).
To identify relevant adipocyte differentiation associated
genes that were targeted by ALP deficiency, we compared the
downregulated genes of ALP deficient CL1 with the upreg-
ulated genes identified during adipocytic differentiation of
CL1. We identified 62 genes that were common (Figure 5(a),
Table 4) and among these genes were genes related to
metabolism (primarily lipid and carbohydrate) and transport
including CYB5B, CHST1, TAP1, ATP8A1, LRP8, PLCD1,
and FABP5 (Table 4). We further performed quantitative
real-time PCR of ALP deficient CL1 cells during adipocyte
differentiation. The following adipocyte-associated genes
were downregulated: PPAR𝛾2, LPL, and aP2 (Figure 5(b)),
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Table 3: Whole genome microarray analysis of two clonal popu-
lations of human bone marrow stromal stem cells: CL1 and CL2
cells. (a) Top 35 highly upregulated genes in CL1 cells versus CL2
cells. (b) Ingenuity Pathway Analysis (IPA) showing the different
physiological system development and function genes found in each
category and the corresponding 𝑝 value. (c) Upper part IPA analysis
showing the categories for skeletal and muscular system development
and function upregulated in CL1 cells and lower part showing genes
upregulated in CL2 cells. NOV = nephroblastoma overexpressed,
IGFBP5 = insulin-like growth factor binding protein 5, ALP, TAGLN
= transgelin, and CDH11 = OB-cadherin (osteoblast).
(a)
Gene ID Fold change CL1 versus CL2
FOLR3 28.4721
CCL3L3 17.936
POSTN 15.5924
SERPINB2 −17.2599
IGFBP5 14.6708
CCL3 13.1203
NOV 11.2921
ACTG2 10.4493
CRYAB 10.0678
PSG4 9.68913
RAB3IL1 9.16897
SCIN 9.13702
MYL9 9.12814
TNFRSF11B 8.86049
TAGLN 8.75581
CDH12 8.06682
SHISA2 8.0291
THBS1 7.86854
SPP1 7.64205
LCE2A 7.41042
TMEM98 7.38011
PSG7 7.12183
MYPN 7.01837
FNDC1 6.88102
TNS3 6.72083
ABI3BP 6.67822
LRP3 6.64307
MMP3 6.34715
FAM167A 6.02684
HSPB2 6.01063
ALPL 6.01022
CTSK 5.87356
CXCL12 5.68572
THY1 4.89445
CDH10 4.86105
(b)
Name 𝑝 value # molecules
Physiological system development and function
Organismal development 7.05𝐸 − 10–1.43𝐸 − 03 181
Embryonic development 1.00𝐸 − 09–1.43𝐸 − 03 154
Organ development 1.00𝐸 − 09–1.43𝐸 − 03 145
(b) Continued.
Name 𝑝 value # molecules
Skeletal and muscular
system development and
function
1.00𝐸 − 09–1.02𝐸 − 03 123
Tissue development 1.00𝐸 − 09–1.43𝐸 − 03 236
(c)
Functions annotation 𝑝 value # molecules
Skeletal and muscular system development and
function upregulated in CL1 cells
Size of bone 1.43𝐸 − 06 24
Differentiation of
osteoblasts 3.84𝐸 − 06 25
Mineralization of
bone 4.93𝐸 − 06 19
Bone mineral density 3.65𝐸 − 05 19
Skeletal and muscular system development and
function upregulated in CL2 cells
Development of
muscle 1.00𝐸 − 09 44
Proliferation of
muscle cells 2.29𝐸 − 06 35
Remodeling of bone 3.63𝐸 − 06 21
Resorption of bone 3.94𝐸 − 06 19
confirming impairment of adipocytic differentiation of ALP
deficient CL1 cells.
4. Discussion
We extensively studied two cell populations within cultured
hBMSC that were identified based on differences in mor-
phology. Cellular and molecular studies revealed differences
in growth, differentiation capacity, and molecular signature.
Our data support the notion of the presence of cellular and
functional heterogeneity among cultured hBMSC.
Cellular heterogeneity of cultured hBMSC is recognized
in an increasing number of reports. Several extrinsic and
intrinsic factors may contribute to the observed hBMSC
heterogeneity. Extrinsic factors include donor-to-donor vari-
ations in the number and quantity of initiating cells, which
result in differences in cell growth rate and differentia-
tion capacity [14, 15]. Intrinsic factors have been examined
employing single cell clonal analysis and revealed variations
in differentiation potential among individual colonies within
hBMSC cultures ranging from the presence of cells with
trilineage (osteoblast, adipocytes, and chondrocyte) potency
to cells with null potency [16]. Also, variations in the ability
of clonal cells to form heterotopic bone when implanted in
vivo have been reported [5]. Our study corroborates these
findings and provides more detailed cellular and molecular
phenotyping of two examples of cell populations that exist
within the heterogeneous hBMSC cultures [17].
Determining the molecular signature of CL1 and CL2
using whole genomemicroarray analysis showed enrichment
of lineage-commitment associated genes inCL1. For example,
insulin-like growth factor 5 (IGFBP5) and interleukin 6 (IL6)
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Figure 3: Validation of whole genome microarray analysis of two clonal populations of human bone marrow stromal stem cells: CL1 and
CL2 cells. Quantitative real-time PCR for highly expressed genes in CL1 cells. NOV = nephroblastoma overexpressed, IGFBP5 = insulin-like
growth factor binding protein 5, ALP, TAGLN = transgelin, and CDH11 = OB-cadherin (osteoblast). Data are presented as fold change in
expression of each target gene normalized to GAPDH (𝑛 = three independent experiments, #𝑝 < 0.001) (see also Table 3).
were 14.7- and 3.3-fold upregulated in CL1 cells, respectively.
Both factors are expressed in osteoprogenitor cells and
important for osteoblast maturation [18]. We also observed
that periostin (POSTN) gene was highly upregulated in
CL1 cells (15.6-fold); POSTN is a 90 kDa secreted protein,
originally identified in murine osteoblast-like cells and is
upregulated by PTH [19]. Several studies employing murine
and human cells have revealed important role of POSTN
in osteoblast differentiation and during development in
intramembranous ossification [20–23]. Another factor iden-
tified in CL1 cells is nephroblastoma overexpression (NOV)
which is a member of the Cyr 61, connective tissue growth
factor (CNN) family. The CCN family of proteins promotes
osteoblast differentiation through interaction with integrins,
WNT, BMP, and NOTCH signaling pathways [24–26]. In
addition, a large number of signaling molecules known to
be regulators of hBMSC lineage specific differentiation, for
example, insulin-like growth factors [27–29], WNT [30–32],
and MAPK [33–35], were enriched in CL1 cells. In contrast,
CL2 expressed high levels of immune-related genes which
may explain the poor differentiation response to osteoblast
or adipocyte lineage. In a recent study the authors used
telomerized hBMSC and showed clearly a clonal population
that had very low in vitro and in vivo differentiation ability;
however they had enhanced immune-related features includ-
ing high IL7 expression. These nullipotent cells expressed
CD317 which was associated with remarkably high basal level
expression of factors with a proinflammatory and antiviral
function [17]. We observed that this molecular phenotype
was associated with distinct ultrastructural characteristics
of the cells. In particular, CL2 had abundant phagocytic
vacuole, microvilli, and lysosomes, features reminiscent of
ultrastructure of immune-regulatory cells. Our data thus
support the increasingly recognized feature that hBMSC
exhibit immune modulatory functions and a part of the
innate immune response [17].
We observed that ALP protein expression and enzymatic
activity were significantly different between CL1 and CL2
cell lines and were thus a potential marker that distinguishes
different cell populations with progenitor functions (CL1)
from cells with nonprogenitor functions (CL2). ALP is
expressed in a wide variety of tissues, including kidneys,
bone, and liver [36, 37], but tissue-nonspecific ALP (ALPL)
is considered a commitment marker for osteoblastic lineage
[13, 38]. However, in a recent study the authors examined the
differentiation potential of a number of hMSC clones in vitro
and in vivo and reported that the hMSC clones with high
levels of ALP expression were committed to trilineage differ-
entiation [13]. Our data corroborate and extend these findings
by reporting the effects of siRNA-mediated inhibition of
ALP that resulted in an impaired hBMSC differentiation not
only to osteoblasts, but also to adipocytes. Also, our results
corroborate earlier studies that demonstrated in human bone
biopsies the presence of ALP expression in bone marrow
adipocytic cells [13, 17]. All these data suggest that ALP is
a “stemness” marker of hBMSC and not just an indicator of
osteoblastic lineage commitment.
While CL1 and CL2 were isolated from telomerized
hMSC cell line, they are relevant to normal human physi-
ology. We observed that the molecular phenotypes of CL1
and CL2 were contained within the molecular signature
of primary hBMSC suggesting that CL1 and CL2 repre-
sent cell populations within the heterogeneous cultures of
hBMSC.We have also previously reported that the molecular
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Figure 4: Effect of alkaline phosphatase (ALP) gene silencing by small interfering RNA (siRNA) on a clonal population of human bone
marrow stromal stem cell CL1. (A) ALP staining at day 3, day 5, or day 7 days of osteoblast differentiation (OB induction). (B) Quantitative
real-time PCR for ALP gene following ALP siRNA transfection at day 0 OB and day 7 of OB. Data are presented as fold change in expression
of each target gene normalized to GAPDH (𝑛 = three independent experiments, #𝑝 < 0.01). Western blotting analysis of day 3 and day 7
after siRNA ALP transfection of CL1 cells, ALPL specific antibody, and B-actin was used. (C) Mineralized matrix formation as visualized
by Alizarin Red S staining in siRNA transfected CL1 cells after 14 days of OB induction. (D) Nile red quantification of mature lipid filled
adipocyte in control noninduced (Cont), adipocyte induced (Adip I), and ALP siRNA transfected cells that are adipocyte induced (ALP
siRNA). Adipocyte induction was carried out for 7 days. ∗𝑝 < 0.05.
phenotype and cellular responses of hMSC-TERT are similar
to those of primary hMSC [10].While we have identified ALP
as a marker that can be used for a prospective identification
of differentiation committed population of hBMSC, we iden-
tified additional distinctive molecular markers of the cells.
For example, IGF-1, IGF-2, and IGF binding protein 5 were
enriched in CL1 compared to CL2. IGFs and their binding
proteins are very well-studied factors that play a role in
hBMSC proliferation and osteoblast differentiation [18]. On
the other hand, annexin A3 as well as several immune-related
genes was highly enriched in CL2 compared to CL1. Future
studies are needed to determine the functional significance
of these molecules in relation to the functional identity of
various cell populations within the hBMSC cultures and
their usefulness as biomarkers to dissect the heterogeneous
population of cultured hBMSC.
Our finding of the presence of functional diversity within
hBMSC cultures that contain progenitor and nonprogenitor
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Table 4: Microarray data analysis showing genes found to be upregulated during adipogenic differentiation and downregulated after ALP
KO.
62 common elements in
“AD up” and “ALP down” Gene name
FC (ALP siRNA versus
control siRNA)
APOBEC3G Apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3G −15.938025
IFI44L Interferon-induced protein 44-like −11.520283
PAQR5 Progestin and adipoQ receptor family member V −6.868241
PNMA2 Paraneoplastic antigen MA2 −5.9695344
DUSP23 Dual specificity phosphatase 23 −5.4786854
CLDN23 Claudin 23 −5.1885047
ANKDD1A Ankyrin repeat and death domain containing 1A −5.1646647
IL8 Interleukin 8 −4.887188
LRRC23 Leucine rich repeat containing 23 −4.7611775
IL6 Interleukin 6 (interferon, beta 2) −4.693139
LIFR Leukemia inhibitory factor receptor alpha −4.6540866
PTGFR Prostaglandin F receptor (FP) −4.457529
FAM134B Family with sequence similarity 134, member B −4.403495
CYFIP2 Cytoplasmic FMR1 interacting protein 2 −4.260462
METTL7A Methyltransferase-like 7A −4.0480843
APOBEC3F Apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3F −3.9502614
CA5B Carbonic anhydrase VB, mitochondrial −3.93889
ITGA10 Integrin, alpha 10 −3.9143775
FMO3 Flavin containing monooxygenase 3 −3.852087
IMPA2 Inositol monophosphatase 2 (human) −3.8374884
CDO1 Cysteine dioxygenase, type I −3.8181455
CCDC68 Coiled-coil domain containing 68 −3.7292893
CXCL1 Chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity,alpha) −3.5942702
IDO1 Indoleamine 2,3-dioxygenase 1 −3.5803545
KCNIP3 Kv channel interacting protein 3, calsenilin −3.5442894
FADS1 Fatty acid desaturase 1 −3.2951858
LSR Lipolysis stimulated lipoprotein receptor −3.2215986
ITGA7 Integrin, alpha 7 −3.1355932
HLA-DMA Major histocompatibility complex, class II, DM alpha −3.1347752
APOBEC3B Apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3B −3.1074922
BMP4 Bone morphogenetic protein 4 −3.0809238
DMBT1 Deleted in malignant brain tumors 1 −3.0760298
RDH5 Retinol dehydrogenase 5 (11-cis/9-cis) −3.066812
EPAS1 Endothelial PAS domain protein 1 −3.0615559
CDKN3 Cyclin-dependent kinase inhibitor 3 −3.052319
GPC6 Glypican 6 −3.0460389
CDK4 Cyclin-dependent kinase 4 −2.9808035
FKBP5 FK506 binding protein 5 −2.9360793
PDE1B Phosphodiesterase 1B, calmodulin-dependent −2.8863106
JAM2 Junctional adhesion molecule 2 −2.884354
TFPI Tissue factor pathway inhibitor (lipoprotein-associated coagulation inhibitor) −2.8578906
NT5M 5󸀠,3󸀠-Nucleotidase, mitochondrial −2.7555947
NFIA Nuclear factor I/A −2.7176137
TSPAN31 Tetraspanin 31 −2.627556
ZNF25 Zinc finger protein 25 −2.6183622
SULF2 Sulfatase 2 −2.5464642
MESP1 Mesoderm posterior 1 homolog (mouse) −2.525513
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Table 4: Continued.
62 common elements in
“AD up” and “ALP down” Gene name
FC (ALP siRNA versus
control siRNA)
BCL2L1 BCL2-like 1 −2.5119667
PLTP Phospholipid transfer protein −2.4767148
TIMP4 TIMP metallopeptidase inhibitor 4 −2.465897
CYP27A1 Cytochrome P450, family 27, subfamily A, polypeptide 1 −2.4572072
TTC39B Tetratricopeptide repeat domain 39B −2.4439611
IL1R2 Interleukin 1 receptor, type II −2.427431
FMOD Fibromodulin −2.4185398
LDLRAD3 Low density lipoprotein receptor class A domain containing 3 −2.4032724
PISD Phosphatidylserine decarboxylase −2.3884957
TMEM100 Transmembrane protein 100 −2.384632
CHST2 Carbohydrate (N-acetylglucosamine-6-O) sulfotransferase 2 −2.3805838
APOBEC3F Apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3F −2.3759322
SCD Stearoyl-CoA desaturase (delta-9-desaturase) −2.3524246
SPAG4 Sperm associated antigen 4 −2.280867
MMD Monocyte to macrophage differentiation associated human −2.2055967
ASS1 Argininosuccinate synthase 1 −2.1725202
GK5 Glycerol kinase 5 (putative) −2.1667244
PDE7B Phosphodiesterase 7B −2.166515
MT1X Metallothionein 1X −2.161843
ACACB Acetyl-CoA carboxylase beta −2.1512873
LEPR Leptin receptor −2.148686
HIF1A Hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcriptionfactor) −2.0954225
HEXDC Hexosaminidase (glycosyl hydrolase family 20, catalytic domain) containing −2.094836
SARM1 Sterile alpha and TIR motif containing 1 −2.0797038
BBS1 Bardet-Biedl syndrome 1 −2.0146718
SERPING1 Serpin peptidase inhibitor, clade G (C1 inhibitor), member 1 −2.0102212
FAM162A Family with sequence similarity 162, member A −2.005807
TCTN1 Tectonic family member 1 −2.0033443
AD up ALP down
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Figure 5: Adipocyte related genes downregulated in ALP knockdown CL1 cells. (a) Venn diagram of whole gene expression analysis of AD
upregulated genes compared with ALP KD downregulated genes. (b) Quantitative real-time PCR of four selected common genes from Venn
diagram including ALPL, PPARg2, aP2, and LPL. Data are presented as fold change in expression of each target gene normalized to GAPDH
(𝑛 = three independent experiments, ∗𝑝 < 0.05, ∗∗𝑝 < 0.01, and ∗∗∗𝑝 < 0.001).
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cell populations has a clinical relevance. It demonstrates that
the progenitor function and the immune modulatory roles
of hBMSC [39] are mediated by specific and distinguishable
populations of hBMSC. Thus, future clinical studies employ-
ing hBMSC should attempt to administer the relevant sub-
population of hBMSC dependent on the experimental aim, as
a novel approach to improving the clinical efficiency, instead
of the current use of heterogeneous hBMSC populations.
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